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Abstract
Background: Chronic lymphocytic leukemia (CLL) cells are often affected by genomic aberrations targeting key 
regulatory genes. Although fludarabine is the standard first line therapy to treat CLL, only few data are available about 
the resistance of B cells to this purine nucleoside analog in vivo. Here we sought to increase our understanding of 
fludarabine action and describe the mechanisms leading to resistance in vivo. We performed an analysis of genomic 
aberrations, gene expression profiles, and microRNAs expression in CLL blood B lymphocytes isolated during the 
course of patients' treatment with fludarabine.
Results: In sensitive patients, the differentially expressed genes we identified were mainly involved in p53 signaling, 
DNA damage response, cell cycle and cell death. In resistant patients, uncommon genomic abnormalities were 
observed and the resistance toward fludarabine could be characterized based on the expression profiles of genes 
implicated in lymphocyte proliferation, DNA repair, and cell growth and survival. Of particular interest in some patients 
was the amplification of MYC (8q) observed both at the gene and transcript levels, together with alterations of myc-
transcriptional targets, including genes and miRNAs involved in the regulation of cell cycle and proliferation. 
Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and 
sensitive patients before treatment. These observations were further confirmed on a validation cohort of CLL patients 
treated with fludarabine in vitro.
Conclusion: In the present study we identified genes and miRNAs that may predict clinical resistance of CLL to 
fludarabine, and describe an interesting oncogenic mechanism in CLL patients resistant to fludarabine by which the 
complete MYC-specific regulatory network was altered (DNA and RNA levels, and transcriptional targets). These results 
should prove useful for understanding and overcoming refractoriness to fludarabine and also for predicting the clinical 
outcome of CLL patients before or early during their treatment.
Background
Chronic lymphocytic leukemia (CLL), the most common
hematologic malignancy in Western countries, is charac-
terized by the accumulation in the blood of monoclonal
CD5+ CD19+ CD23+ B lymphocytes mainly arrested in
G0/G1 phase of the cell cycle. Various cytogenetic abnor-
malities are often found in CLL B cells. Importantly, a few
conserved aberrations are consistently observed in asso-
ciation with rapid disease progression and short survival
times [1]. These aberrations affect chromosome 12 (tri-
somy), 13q14 (microRNA-15a (miR-15a)/miR-16-1),
17p13 (TP53) and 11q22 (ATM). CLL B cells fail to fulfill
their immunological role and are not able to achieve
either their final differentiation or programmed cell
death.
Due to their potential to kill non-dividing cells [2],
purine nucleoside analogs such as fludarabine (9-b-D-
arabinofuranosyl-2-fluoroadenine) are often used as first-
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line therapy to prolong the progression-free survival of
CLL patients. In addition to the use of fludarabine as a
single chemotherapeutic agent, new attractive therapies
combining fludarabine with chimeric monoclonal anti-
bodies were recently successfully introduced.
The mechanisms underlying the toxic effects of fludar-
abine have been studied in vitro. In proliferating cells, flu-
darabine requires DNA synthesis for cytotoxicity and
induces apoptosis in a cell cycle-dependent manner by
inhibiting several enzymes involved in DNA metabolism
[3]. In quiescent human lymphocytes, fludarabine incor-
poration inhibits DNA synthesis during DNA repair and
thus induces irreversible damage triggering disruption of
mitochondrial integrity and apoptosis [4,5]. The p53 sig-
naling pathway, which provides a major control mecha-
nism to regulate cell cycle arrest and apoptosis in
response to DNA damage, is also involved in fludarabine-
mediated cytotoxicity. Post-translational modifications of
p53 regulate its activity and determine cell fate by modu-
lating the class of target genes inducing G1 or G2 arrest,
DNA repair and/or apoptosis depending on the extent
and severity of damages [6]. Killing of resting lympho-
cytes was previously reported to act by p53-independent
and -dependent manners in vitro and in vivo [2]. In addi-
tion to p53-related aspects, the resistance to cancer treat-
ment in CLL has been connected to biochemical
alterations targeting membrane transporters, deoxycyti-
dine kinase, and cytoplasmic 5'-nucleotidase cN-II activi-
ties, and more recently to changes in the levels of miR-
34a [7], a miRNA belonging to the class of small non-cod-
ing RNA molecules mediating post-transcriptional gene
silencing. MicroRNAs regulation is currently the subject
of intense research, and differential expression of miR-
NAs has been reported in B cells of healthy donors and
CLL patients [7-10].
Previous in vitro studies of fludarabine were based on
the treatment of cells in culture and did not take in con-
sideration parameters like pharmacokinetics and cell
microenvironment which represent critical factors for the
outcome of the treatment in vivo. Although fludarabine
has been known for twenty years to have considerable
activity against CLL [11], its mode of action at the molec-
ular level in vivo is only poorly described. Thus, half the
cases of resistance that manifest after several rounds of
fludarabine treatment [12] cannot be explained by p53
defects [13]. In this study, we have addressed the response
of CLL B cells to fludarabine in vivo. We have investigated
the mechanisms involved in the resistance to fludarabine
and identified molecular markers predictive of poor clini-
cal responses. Rare genomic aberrations were detected
that target genes playing prominent roles in the regula-
tion of important cellular mechanisms. We report on a
set of genes and miRNAs that could predict the clinical
outcome of CLL patients and refine prognosis before che-
motherapeutic treatment. Finally, we discuss the perspec-
tives offered by our findings for improving CLL
therapeutic strategies, overcoming resistance in CLL
patients and enhancing the overall survival of previously
treated patients with impaired prognosis.
Methods
Patients and samples
This research was approved by the Comité National
d'Ethique de Recherche (Luxembourg, N°200509/05) and
participants gave written informed consent in accordance
with the Declaration of Helsinki. CLL was diagnosed
according to standard clinical and laboratory criteria.
Patients received fludarabine (25 mg/m2 for 5 days per
cycle, Fludara®, Bayer Healthcare Pharmaceuticals) dur-
ing their therapy in the departments of hematology/
oncology (Centre Hospitalier du Luxembourg and Uni-
versity Hospital of Reims). Clinical details, previous treat-
ments and genomic characteristics of patients (N = 18,
CLL-1 to -18) are summarized in Additional file 1. CLL
patients showing an important decrease in lymphocyte
count after treatment and not requiring further therapy
were classified as sensitive (called S) to fludarabine. Other
patients were classified as refractory to the treatment
(called R) as they showed only a moderate decrease of
their lymphocyte count after treatment, relapsed very
quickly, and required further therapies. Patient CLL-3R
died because of CLL complications two months after the
beginning of the treatment. The treatment of patient
CLL-2S was stopped because of a cytomegalovirus re-
activation. In addition, a validation cohort of CLL
patients (N = 21, CLL-19 to -39) was used to confirm the
prognostic role of genes and miRNAs on the evaluation
of the resistance to fludarabine in vitro.
Peripheral blood samples were collected from patients
before their treatment (T0) for patients CLL-1 to -18, and
after 1 to 9 days of fludarabine treatment in vivo (T1, T2,
and T9, for patients CLL-1 to -6 only), and from CLL
patients recruited for the in vitro validation (CLL-19 to -
39). The isolation of mononuclear cells was performed
from whole blood by density gradient centrifugation
using the Lympho isolation medium (MP Biomedicals,
France). From the collected cells, the proportion of B cells
was always greater than 90%. Otherwise, a negative selec-
tion was performed to eliminate T and NK cells and
monocytes/macrophages with help of the Dyna-
beads®CD2 and CD14 (Dynal Biotech, Norway), respec-
tively.
Cytotoxicity assay
Cell viability was measured by using the tetrazolium salt-
based Cell Counting Kit-8 assay (Dojindo Molecular
Technologies, Inc., Eke, Belgium). Cells from patients
CLL-19 to -39 were washed twice in PBS and cultured atMoussay et al. Molecular Cancer 2010, 9:115
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a density of 1.5 × 106/ml (100 μl per well in 96-well plates)
in RPMI-1640 supplemented with 10% of fetal calf serum.
Cells were treated for 48 h with a range of fludarabine
(Fludara®, Bayer Healthcare) concentrations (0-10 μM),
including clinically achievable concentrations (1.5 - 4.5
μM, [14]). CCK-8 reagent was then added and plates were
incubated before measuring the absorbance at 450 nm.
DNA isolation, array-based CGH, cytogenetics, and FISH 
analyses
All genetic analyses were performed on sample T0 prior
to treatment. Comparative Genomic Hybridization
(CGH) array analysis was performed to identify genomic
aberrations in B cells of patients CLL-1 to -6 only. Briefly,
DNA of selected B cells was isolated using the QIAamp
DNA Blood Mini Kit (QIAGEN) following the instruc-
tions of the manufacturer. After enzymatic digestion
(AluI and RsaI), 2 μg of patient DNA and control Human
Genomic DNA (Promega) were coupled with the
Genomic DNA Labeling Kit PLUS (Agilent, France) to
cyanine 5 and 3, respectively, and then hybridized (40 h at
65°C) on Agilent 60-mer 244 K Human Genome CGH
Microarray following protocols of the manufacturer.
Images were analyzed with Feature Extraction® software
(Agilent) and data analysis was performed with CGH-
Analytics®  (Agilent) using the Aberration Detection
Methods ADM1 and ADM2.
Conventional cytogenetic analyses were available for
patients CLL-1 to -18. Fluorescence in situ hybridization
(FISH) analysis was performed using the LSI ATM-2/
CEP11, LSI p53/CEP17, LSI S13S319 with CEP 12, LSI
IGH/BCL2, LSI IGH/CCND1 and LSI PML/RARA fluo-
rescent probes (Vysis/Abbott, Belgium) according to
standard protocols.
RNA isolation
The procedure followed was similar for cells from
patients treated in vivo and cells incubated in vitro. The B
cells were centrifuged at 350 g for 5 min at 20°C and the
pellet was lysed in Trizol®  (Invitrogen) following the
instructions of the manufacturer with slight modifica-
tions. Briefly, after addition of chloroform and vigorous
shaking, the samples were transferred into 1.5 ml-Phase
Lock Gel Heavy tubes (Eppendorf) and centrifuged for 10
min (12,000 g at 4°C). The aqueous phase was recovered
and 5 μg of RNase-free glycogen were added as carrier.
Total RNA was precipitated with isopropyl alcohol over-
night at -20°C, centrifuged at 12,000 g for 10 min at 4°C,
and washed once with 75% ethanol. After treatment with
DNase (DNA-free™, Ambion), RNA quantity and quality
were evaluated with the NanoDrop® ND-1000 spectro-
photometer and the Agilent 2100 bioanalyzer, respec-
tively.
TP53 and Immunoglobulin heavy-chain sequence analysis
We analyzed DNA samples from CLL patients by PCR
and fluorescent sequencing to determine TP53  muta-
tional status (exon 2-10) using Big Dye Terminator kit
and ABI 3130 sequencer (Applied Biosystems). The
primer sequences are available upon request.
The B lymphocyte Ig gene rearrangement and muta-
tional status was determined by IgVH-specific RT-PCR
and sequencing [15]. Complementary DNA (cDNA) was
obtained by reverse transcription of 2 μg RNA by using
the Reverse Transcriptase Core kit with random nonam-
ers (Eurogentec, Belgium). Fifteen microliters of cDNA
were amplified by PCR using a mixture of primers [15]
specific for VH1-VH6 sequences together with either a 3'
primer specific for the JH consensus region or a 3' primer
specific for the constant region of the IgM locus. Amplifi-
cation products were gel-extracted and sequenced.
Nucleotide sequences were compared to the international
ImMunoGeneTics information system®  (IMGT/V-
Q U E S T )  a n d  t o  t h e  N C B I  I g  B L A S T  d a t a b a s e s .  T h e
homology of the sequence with the closest germline
counterpart was assessed and sequences with 98% or
greater homology to germline-encoded VH gene were
categorized as unmutated.
Complementary DNA microarrays
Microarray experiments were performed with samples
from CLL patients sensitive (CLL-1, -2, -4, -5) and resis-
tant (CLL-3 and -6) to fludarabine. As the treatment of
patients can be assimilated to a time course experiment,
the commonly used two-channel microarray experiment
loop design was chosen [16]. Each sample was hybridized
to two different samples in two different dye orientations
(T0 vs T1, T1 vs T2, T2 vs T9, T9 vs T0) in quadrupli-
cates. Briefly, 1 μg of total RNA from B cells of patients
CLL-1 to -6 only was amplified and labeled with the
Amino Allyl MessageAmp™ II aRNA Amplification Kit
(Ambion, UK). The coupling reaction was performed fol-
lowing the protocol of the manufacturer using Alexa
Fluor® Reactive Dye Decapacks (AF555 and 647, Molecu-
lar Probes). Alexa Fluor®-aRNA were hybridized for 16 h
on cDNA microarrays (Operon human version2 oligonu-
cleotide library, University Medical Center Utrecht, The
Netherlands). Microarrays were scanned at 10-μm reso-
lution with two laser channels (532 and 635 nm) using a
GenePix® 4000B scanner and GenePix® Pro 6.0 (Molecular
Devices Corporation, CA) at variable photomultiplier
tube (PMT) gains (< 1% saturated spots).
Microarray data were deposited in the EMBL-EBI
ArrayExpress public repository (Accession number E-
MTAB-70). The image analysis and spot selection were
performed with MAIA 2.7 (Institut Curie, France) as pre-
viously described [17]. Acuity® 4.0 (Molecular Devices,Moussay et al. Molecular Cancer 2010, 9:115
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CA) was used for data processing (dye-swap, Lowess nor-
malization), warehousing and visualization. A few
microarrays were excluded from analysis based on the
results of Pearson cross-correlation coefficient (data not
shown). Data were subjected to statistical examination
with the SAM add-on for Microsoft Excel (Significance
Analysis of Microarrays, Stanford, CA; using centered
median, 100 permutations). Missing values were imputed
using the k-nearest neighbor method (k = 10). Delta val-
ues were adjusted to obtain gene lists with a false discov-
ery rate (FDR) ≤ 1% for one-class analysis and ≤ 5% for
two-class analysis. Genes identified by SAM two-class
analysis as regulated in CLL B cells after 24 h of treatment
with fludarabine in vivo were classified by enriched gene
sets wit h t he Gene Set Enrichment Analysis algorithm
(GSEA 2.05, database Dec 2009; Broad Institute, MA).
Differentially regulated genes were clustered as molecular
interaction networks with Ingenuity Pathway Analysis
(IPA 8.0, database Nov 2009; Ingenuity Systems, CA).
Quantitative RT-PCR
For validation of microarray data, specific primers were
purchased from Eurogentec (primer sequences available
upon request). Five nanograms of cDNA were used in a
25 μl PCR reaction mixture containing 12.5 μl SYBR®
Green PCR MasterMix, and 300 nM of each primer. PCR
amplifications were performed on ABI 7300 Real-Time
PCR System (40 cycles at 95°C - 15 sec and at 60°C - 60
sec). Values were normalized according to previous rec-
ommendations [18] to both 28S rRNA and  FLOT2  by
using the average Ct value of housekeeping genes and
were processed by using the Ct value obtained before
treatment as calibrator (2-Δ ΔCt calculation method).
M i c r o R N A s  t o  b e  t e s t e d  w e r e  c h o s e n  a s  i )  t h e y  w e r e
reported as regulated in CLL ii) they modulate genes
involved in apoptosis and cell cycle iii) they are known
transcriptional targets of Myc. The detection of miRNAs
was performed by TaqMan®-based qPCR by using 50 ng
of total RNA as starting material. The TaqMan miRNA
Reverse Transcription and TaqMan 2X Universal PCR
Master Mix, No AmpErase UNG together with specific
TaqMan miRNA Assays (all Applied Biosystems) were
used for RT and PCR reactions (35 cycles at 95°C - 15 sec
and at 60°C - 60 sec). All miRNA expression values were
normalized to both 18S rRNA and FLOT2 (2-ΔΔCt calcula-
tion method). ZAP-70 and LPL quantification were per-
formed as described before [19].
Results
Common genomic abnormalities observed before 
fludarabine treatment
Eighteen CLL patients were given one to six fludarabine
cycles (25 mg/m2 per day for 5 days) and classified as sen-
sitive or resistant to the treatment based on changes in
lymphocyte counts, relapse, and requirement for further
therapy. We first analyzed common genomic abnormali-
ties in samples collected prior to treatment. Results
obtained by array-based CGH analysis and targeted genes
are presented in Table 1 and Additional file 1. Classical
abnormalities affecting 13q14, 11q22, chr 12, and 17p13
were detected. Sequencing of TP53 gene indicated the
presence of a V274G point mutation in the exon 8 of B
cells from patient CLL-5S. In patient CLL-3R, a 2nt-dele-
tion in exon 7 induced the presence of a stop at codon 239
(truncated protein). In patient CLL-6R, although one
allele was deleted, the second one did not present any
Table 1: Genomic aberrations and targeted genes observed in CLL patients resistant to fludarabine.
Genomic aberrations Type of aberration Targeted gene(s)
idic(3q) Deletion 3p XPC, RAD18, PCAF
Gain 3q BCL6, FAIM, p63
7q21, 7q36 1 Gain MDR family genes
idic(8q) Deletion 8p TNFRSF10 family genes
Gain 8q MYC
9p24p21 2 Deletion JAK2, p16INK4, CDKN2B, SMARCA2
11q23 Deletion ATM
12p13.31p12 Deletion p27
13q14.2q14.3 Deletion DLEU genes, Rb, miR-15a, miR-16-1
15q15q26 Gain MGA, PML, BLM, cyclin B2, and 53BP1
idic(17q) Deletion 17p p53, MNT
Gain 17q STAT3, SPOP, RAD51L3, RARA, RDM1
1 These aberrations were observed only in patient CLL-6R
2 This aberration was observed only in patient CLL-3RMoussay et al. Molecular Cancer 2010, 9:115
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mutation (Additional file 1). Interestingly, among the ten
patients clinically resistant to fludarabine, five (50%) pre-
sented with wild-type TP53 gene, underlying the impor-
tance of factors other than p53 in the mechanisms
leading to resistance to this drug. In addition, no influ-
ence of ZAP-70 expression, IgVH status or deletions
affecting 11q or 13q on the response to treatment could
be identified. In summary, no difference was observed
between patients in regards to their sensitivity or resis-
tance to the treatment when taking in consideration clas-
sic clinical parameters and history of previous
treatments.
Genetic complexity of resistant CLL B cells before 
fludarabine treatment
A l t h o u g h  t h e  B  c e l l s  f r o m  m o s t  p a t i e n t s  d i s p l a y e d
genomic imbalances (Additional file 1), conventional
cytogenetics and CGH-arrays indicated that the extent
and complexity of these chromosomal aberrations were
higher in B cells from the resistant patients, as illustrated
by the losses, gains, and dicentric isochromosomes
(idic(17)(p12) and idic(8)(p12) observed in patients CLL-
3R and CLL-6R. Thus, a gain on 15q15.1q26.3, where the
genes MGA, PML, BLM, cyclin B2, and 53BP1 are located
(Table 1), was detected in both patients by CGH and con-
firmed by FISH analysis (Additional files 2 and 3). We
also identified a deletion of 9p24.3p13.1 targeting JAK2,
the tumor suppressors CDKN2A  and  CDKN2B  and
SMARCA2 (Brm) in patient CLL-3R. Finally, deletions on
6q14.1q14.3, 14q24.2q24.3 and 14q32.11q32.12 and alter-
ations on chromosome 7 (MDR genes) rarely observed in
CLL were also detected in B cells of patients CLL-3R and
-6R, respectively.
Gene expression profile in CLL B cells in response to 
fludarabine treatment in vivo
To gain more knowledge about the mechanisms underly-
ing the cellular response to fludarabine, we next exam-
ined changes in gene expression profiles induced by
fludarabine  in vivo. To this end, we identified genes
whose expression was altered by fludarabine in B cells
from six patients given a fludarabine cycle (5 days). Sam-
ples were collected prior to treatment as well as 1, 2 and 9
days following the first administration. A one-class SAM
analysis was run to specify differentially expressed genes
in each patient and time transition in response to the
treatment. The four sensitive patients responded simi-
larly to the treatment at all time points. In addition, the
responses after 24/48h of treatment were very similar.
Fludarabine-regulated genes (FDR ≤ 1%) together with
their biological function and fold changes are listed in the
Additional file 4. Pathway analysis indicated that most of
genes identified in this study as regulated were involved
in programmed cell death, cell cycle, p53 signaling, cell
stress response, response to DNA damage, and cell-to cell
signaling and interaction (p < 0.05, data not shown), con-
firming previous studies [4,5,15,20]. Therefore we
focused our investigations on these biological pathways.
We noted that most of regulated genes were p53 or Myc
transcriptional targets. Therefore a molecular interaction
network centered on both transcription factors was cre-
ated with the most regulated genes after 24h of fludara-
bine treatment in vivo (Fig. 1A). Interestingly, the p53
response was highly induced (dark red) by fludarabine as
indicated by the strong up-regulation of p21, PLK2, cyclin
G1, DDB2, and XPC, consistent with the notion that p53
signaling provides an important pathway leading to cell
cycle arrest and cell death in response to fludarabine.
Regulators targeting p53 for degradation and important
cell growth regulators were also over-expressed after 24/
48h of treatment. On the other hand, a strong down-reg-
ulation of several genes was induced by the treatment in
all sensitive patients (dark green). Among these were
genes regulated by the MYC  and  STAT1  transcription
factors involved in cell survival (XIAP and  BIRC5/sur-
vivin), cell growth and proliferation (IL7, IL7R), and DNA
repair and replication. Lymphoid markers, chemokines,
cytokines, and their receptors were also down-regulated.
A more detailed list of regulated genes and functions
can be found in the Additional file 4.
After 9 days of treatment, a different molecular
response was observed; most p53-target genes were now
down-regulated, whereas other genes involved in the
control of growth and apoptosis were still up-regulated
(data not shown).
Gene expression profile in resistant CLL B cells in vivo
SAM one-class analysis
An overlay of gene expression data obtained in cells of
resistant patients was performed on the molecular inter-
action network built with gene expression of sensitive
patients. We observed strikingly different molecular
responses as few p53-target genes were regulated in cells
of resistant patients (Fig. 1B). In contrast, other genes
were regulated by MYC and p53 in B cells of resistant
CLL patients (Fig. 2A). The conserved families of PI3K
and 14-3-3 proteins were highly regulated in B cells of
resistant patients together with cell cycle and cell death/
survival regulators. Genes significantly regulated in resis-
tant patients were also involved in nucleoside and nucle-
otide metabolism (UMPS), the response to DNA damage
(PARP1) and replication (MCM7) ,  i n  c o n t r a s t  t o  w h a t
observed in cells of sensitive patients (Fig. 2B). A more
detailed list of regulated genes and functions can be
found in the Additional file 5.
SAM two-class analysis
A direct comparison of the responses elicited by fludara-
bine in CLL B cells from sensitive and resistant patientsMoussay et al. Molecular Cancer 2010, 9:115
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Figure 1 Molecular interaction network of fludarabine-regulated genes in cells of sensitive CLL patients in vivo. A group of genes highly reg-
ulated by fludarabine in sensitive patients (following a 24h exposure in vivo) was clustered in a network around the transcription regulators TP53 and 
MYC using the Ingenuity Pathway Analysis software (IPA 8.0, database Nov 2009). A, Gene expression values obtained from sensitive patients were 
overlaid on the network. B. Gene expression values obtained from resistant patients were overlaid on the network.Moussay et al. Molecular Cancer 2010, 9:115
http://www.molecular-cancer.com/content/9/1/115
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Figure 2 Molecular interaction network of fludarabine-regulated genes in cells of resistant CLL patients in vivo. A group of genes highly reg-
ulated by fludarabine in resistant patients (following a 24h exposure in vivo) was clustered in a network around the transcription regulators TP53 and 
MYC using the Ingenuity Pathway Analysis software (IPA 8.0, database Nov 2009). A. Gene expression values obtained from resistant patients were 
overlaid on the network. B. Gene expression values obtained from sensitive patients were overlaid on the network.Moussay et al. Molecular Cancer 2010, 9:115
http://www.molecular-cancer.com/content/9/1/115
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was performed by SAM two-class analysis followed by
unsupervised Pearson hierarchical clustering, revealing
dramatic differences in the patterns of gene expression
induced by the drug. As shown in Fig. 3, a set of 537 genes
was significantly differentially regulated between cells of
resistant and sensitive patients after 24h of fludarabine
treatment. The genes identified by SAM analysis can be
found in the Additional file 6. Among these genes, 207
were over-expressed in resistant while repressed in cells
of sensitive patients. Conversely, 330 genes were induced
in sensitive while repressed in cells of resistant patients.
These genes were classified by gene sets and biological
functions with the GSEA algorithm. The genes up-regu-
lated in B cells of sensitive patients were mainly involved
in p53 signaling, DNA damage response, DNA repair, cell
death, and cell cycle (Table 2). These functions were
appreciably different from those represented in resistant
patients in whom the majority of genes were implicated
in the control of lymphocyte proliferation, cell growth
and survival, DNA replication and repair, and functions
o f  m a t u r e  l y m p h o c y t e s .  G e n e  s e t s  a l s o  c o n t a i n e d
responses mediated by MYC, EGR2, and APC transcrip-
tion factors.
A related analysis identified 316 and 352 genes differen-
tially regulated after two and nine days of treatment,
respectively, representing biological functions very simi-
lar to those regulated after one day of treatment (data not
shown).
Cytotoxicity of fludarabine on CLL samples in vitro
As a first step to validate in vitro some of the candidate
marker genes identified above, we carried out cytotoxic-
ity assays on cells from a cohort of CLL patients (N = 21)
with the aim to identify fludarabine-sensitive and -resis-
tant cells. The definition of resistance to fludarabine in
vitro is still a matter of debate; figures have been pro-
posed that range from 20% of cell death following a 24-h
exposure to 1 μM fludarabine [21] to an IC50 of 10 μM
after 72h of treatment [22], and no consensus exists about
the dose and time of treatment for in vitro studies. In our
experiments, cytotoxicity was measured 48h after expo-
sure to fludarabine (0-10 μM) and resistance was defined
using a threshold cut-off based on the response obtained
with all 21 samples. Thus, although we observed a wide
distribution of responses to the treatment among
patients, two groups could be clearly identified, and
patients displaying an IC50 > 7 μM after 48h of treatment
in vitro were considered resistant (Additional file 7). Six-
teen over twenty-one (76.2%) CLL patients were identi-
fied as sensitive to fludarabine in vitro as the inhibitory
concentration (IC50) was lower or equal to 4 μM, which is
very close to maximum dose achievable in clinics (4.5
μM, [14]). Five patients were classified as resistant (IC50 >
7 μM), of which four had an IC50 greater than 10 μM.
We then used these two groups of cells to assess the
expression of our candidate marker genes and miRNAs
(see below) in vitro.
Validation of gene and miRNA markers of cell resistance to 
fludarabine
Microarray data were first validated by RT-qPCR in sam-
ples CLL-1 to -6. Twenty genes with various intensities of
expression are presented in Fig. 4. Although some dis-
crepancies of intensity were observed, overall gene
e x p r e s s i o n  p r o f i l e s  a s s e s s e d  b y  q R T - P C R  a f t e r  2 4 h  o f
treatment with fludarabine were consistent with cDNA
microarray data. Interestingly, when qPCR were per-
formed to validate microarray data, we observed that the
baseline expression of several genes greatly differed
between CLL patients before treatment. Consistent with
our previous observations, lower levels of transcripts of
genes involved in early DNA damage detection and p53
signaling were observed in resistant compared to sensi-
tive patients (Table 3). Transcripts of other genes impli-
cated in DNA repair and proliferation were in contrast
more abundant. Interestingly, MYC  and  SULF2  tran-
scripts were identified as strongly over-represented in B
cells of patients CLL-3R and -6R resistant to fludarabine
in vivo (20-34 and 72-157 fold, respectively). This obser-
vation was confirmed on a larger cohort of CLL patients
treated with fludarabine in vivo (N = 18, Fig. 5A) or in
vitro (N = 21, Fig. 5B) with both genes being significantly
over-expressed in samples of resistant patients obtained
before treatment (p < 0.05).
Three miRNAs, miR-29a, miR-181a, and miR-221, have
been shown to be regulated in CLL [8] and play impor-
tant regulatory roles in oncogenesis and cell cycle regula-
tion [23,24]. In addition, miR-29a and miR-181 are
transcriptional targets of MYC family members which
repress miR-29a [25] but induce miR-181a transcription
[26]. This prompted us to also investigate miRNA expres-
sion in fludarabine-sensitive and resistant cells. We found
that miR-181a and miR-221 were strongly over-repre-
sented in cells of resistant patients (p = 0.015 and p =
0.05), and that miR-29a was significantly down-regulated
in patients resistant in vitro (p = 0.026) (Fig. 5). Other
miRNAs (miR-34a, miR-150*, and let-7e) were also
repressed but not significantly (p > 0.05, data not shown).
In summary, we showed in cells of CLL patients resis-
tant to fludarabine an over-expression of MYC, SULF2,
miR-181a, and miR-221 together with a decrease in miR-
29a level.Moussay et al. Molecular Cancer 2010, 9:115
http://www.molecular-cancer.com/content/9/1/115
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Table 2: Gene set enrichment analysis (GSEA) of CLL B cells from fludarabine-sensitive and -resistant patients
Function/Pathway Gene sets enriched in sensitive 
patients
Size NES NOM p-val
p53 response STRESS_ARSENIC_SPECIFIC_UP 6 1.76 0.002
P53PATHWAY 6 1.61 0.004
HSA04115_P53_SIGNALING_PATHWAY 13 1.62 0.006
P53GENES_ALL 9 1.53 0.021
P53_BRCA1_UP 5 1.50 0.030
STRESS_P53_SPECIFIC_UP 5 1.44 0.031
KANNAN_P53_UP 9 1.51 0.032
DNA damage response DNA_DAMAGE_SIGNALING 13 1.69 0.008
UVC_TTD-XPCS_COMMON_DN 8 1.69 0.014
CIS_XPC_DN 10 1.73 0.017
DNA repair, cell cycle, 
apoptosis
BLEO_HUMAN_LYMPH_HIGH_4HRS_UP 9 1.59 0.028
BAFF/APRIL receptor MOREAUX_TACI_HI_VS_LOW_UP 8 1.45 0.023
hTERT-regulated 
genes
SMITH_HTERT_DN 5 1.57 0.028
ROTH_HTERT_DIFF 7 1.48 0.049
NF-KB signaling HINATA_NFKB_UP 6 1.53 0.032
Cell death APOPTOSIS 6 1.55 0.034
BRENTANI_DEATH 6 1.55 0.034
APOPTOSIS_GENMAPP 5 1.56 0.035
Cell cycle CELL_CYCLE_KEGG 6 1.52 0.044
CELL_CYCLE 6 1.52 0.044
TAKEDA_NUP8_HOXA9_16D_DN 11 1.43 0.045
Function/Pathway Gene sets enriched in resistant 
patients
Size NES NOM p-val
T lymphocyte 
proliferation
GOLDRATH_HP 14 1.61 0.008
EGR2-regulated genes LE_MYELIN_UP 6 1.58 0.009
Genes involved in 
cholera infection
HSA05110_CHOLERA_INFECTION 5 1.63 0.023
Myeloma cell growth 
and survival
CHAUHAN_2ME2 5 1.50 0.042
DNA and RNA 
metabolism
WERNER_FIBRO_DN 5 1.45 0.059
p53 response, anti-
apoptosis, DNA repair
UVB_SCC_DN 6 1.39 0.086
Myc-regulated genes MYC_ONCOGENIC_SIGNATURE 8 1.37 0.061
Functions of mature T 
lymphocytes
LEE_TCELLS2_UP 46 1.27 0.084
Hematopoeitic stem 
cell genes
BYSTRYKH_HSC_TRANS_GLOCUS 29 1.38 0.070
APC-regulated genes SANSOM_APC_LOSS5_UP 10 1.47 0.084
NES Normalized Enrichment Score, NOM p-val Nominal p-valueMoussay et al. Molecular Cancer 2010, 9:115
http://www.molecular-cancer.com/content/9/1/115
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Discussion
The present study was first designed to improve our
understanding of fludarabine-mediated killing of CLL
cells in vivo. The response of cellular emergency mecha-
nisms to DNA damage includes the transcriptional acti-
vation of mediators regulating cell cycle, DNA repair or
apoptosis. Here we observed in sensitive B cells a strong
up-regulation of p53-target genes (Fig. 1A and Additional
file 4); thus confirming the results of previous in vivo
studies [15,20]. We also detected a marked increase in the
level of CDK4, PLK2, and cyclin G1 and a down-regula-
tion of the cdk-inhibitor p27, suggesting regulatory roles
of these genes after fludarabine treatment in cells under-
going apoptosis. Novel regulators identified in this study
(Additional file 4), such as the p53-target exonuclease
AEN, the ER-localized scotin SHISA5, the speckle-type
POZ protein SPOP, the Polo-like kinase PLK3 and the
apoptosome inducer ANP32A, are required for DNA deg-
radation and ER stress during p53-dependent cell cycle
arrest and apoptosis [27-31]. Finally, CASP2, which is
involved in p53-mediated apoptosis [32], and its inducer
ITGB3BP were up-regulated too, further supporting the
role of caspase-2 in the mechanisms underlying the cyto-
toxicity of fludarabine [32].
Albeit delayed, partial cellular death and induction of
apoptosis-related genes were observed in the monoclonal
population of resistant patients. This suggests that fludar-
abine entered the cells and was efficiently activated to its
phosphorylated form. Therefore we did not investigate
the biochemical aspects of resistance but we focused on
the molecular response of the resistant cells. While flu-
darabine is known to inhibit DNA repair, we observed an
over-expression of genes related to cell cycle, growth and
survival, and DNA and RNA metabolism suggesting that
cellular maintenance mechanisms operate in lympho-
cytes from resistant patients (Table 2 and Additional file
Figure 3 Clusters of differentially expressed genes in CLL B-cells following treatment with fludarabine in vivo. A set of 532 genes were differ-
entially expressed (DE) between CLL B cells of sensitive and resistant patients after 24 hours of treatment. Statistical analysis was performed by SAM 
2-class analysis and significant DE genes were clustered using Acuity 4.0 (Pearson hierarchical clustering). Microarray replicates (M1 to M4) from sen-
sitive and resistant patients are depicted in blue and orange, respectively.Moussay et al. Molecular Cancer 2010, 9:115
http://www.molecular-cancer.com/content/9/1/115
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5). This combination of factors could explain resistance
as cells exhibit a reduced p53-response whilst displaying
active DNA repair and proliferative responses. Factors
negatively regulating p53 activation and increasing its
degradation were also over-expressed (DDX17,  SNCB,
SOD1, and TRIM28  [KAP1]). Interestingly, KAP1 pro-
tects cells from apoptosis in response to DNA damage
[33] and represses p21, GADD45A, Puma, Noxa, and Bax
transcription, suggesting the repression of p53-depen-
dent apoptotic effectors by KAP1-dependent mecha-
nisms [34].
Recently, the availability of growth factors and angio-
genesis have been recognized as important factors in CLL
pathology [35] Our analysis of the pathways regulating
cellular growth and proliferation revealed that transcripts
of the 6-O endosulfatase SULF2, a novel p53-target gene
[36], were differentially regulated in patients and dramat-
ically more abundant in cells of resistant patients (Fig. 5).
Contradictory functions of SULF2 have been reported in
different models. Sulf2 has been shown to promote cell
proliferation and migration by releasing VEGF and SDF-1
from heparin/heparin sulfate proteoglycans in the extra-
cellular matrix [37]. The abundance of SULF2 transcripts,
Figure 4 Validation of cDNA microarray gene expression data by RT-qPCR. Twenty differentially regulated genes identified in the microarray 
analysis were validated in the four CLL cases sensitive to fludarabine by RT-qPCR. B lymphocytes were isolated from blood of patients treated 24h in 
vivo with fludarabine. Expression levels of the targets were normalized to both housekeeping genes and Ct values obtained before treatment were 
used as calibrators. See Methods for details.Moussay et al. Molecular Cancer 2010, 9:115
http://www.molecular-cancer.com/content/9/1/115
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observed in this study in resistant patients prior to treat-
ment, is in agreement with its proposed pro-angiogenic
and oncogenic effects [38-40]. However fludarabine was
found to increase the level of SULF2 mRNA in cells of
sensitive patients only (Additional file 4). This finding
also supports the notion that SULF2 is induced by anti-
metabolites [41] and can be a potent inhibitor of hemato-
logic tumor growth in vivo [42]. We also detected a flu-
darabine-induced over-expression of the growth
inhibitors SPRY1 and CAV1 [43] mRNA in all conditions.
Further investigations about tumor microenvironment
will be required to understand the growth of malignant
CLL cells in vivo.
Next we sought to investigate the genomic abnormali-
ties associated with resistance. In addition to gains on
chr7 (MDR  genes) previously described [44] and a 9p
deletion targeting SMARCA2 necessary for induction of
p53 targets [45], we detected an important gain on the
15q arm. The presence of p53-cooperating genes on 15q
reinforces the interest for this aberration in atypical CLL
treated with DNA damage-inducing agents. In addition
to these aberrations, we identified three isochromosomes
in CLL cells leading to loss of heterozygosity. Thus iso-
chromosomes may have clinical implications even though
they are probably not primary lesions. As a consequence
of the presence of the idic(8q), we observed a gain on 8q
bearing the c-MYC oncogene in some resistant patients,
which led us to investigate MYC expression in our sam-
ples. We observed the strong over-expression of MYC
transcripts in CLL cells of resistant patients before treat-
ment (Fig. 5A). This regulation was later confirmed in
cells resistant to fludarabine in vitro, which also displayed
higher levels of SULF2 (Fig. 5B).
We then considered Myc transcriptional targets and
identified several differentially expressed genes and miR-
NAs that are direct targets of Myc in CLL B cells. An
important conclusion of our work is that the Myc target
gene network was up-regulated in cells that were resistant
to fludarabine, whereas the p53 target gene network was
down-regulated in these cells. For instance, over-expres-
sion of the Myc targets CDK4  and  CCNB1
(cyclinB1)[46,47], which is suggestive of cell cycle pro-
gression, was observed in cells from our resistant
patients. Interestingly, c-Myc and p53 have opposite
effects on the regulation of cyclin B1, and induction of
chromosomal instability by cyclin B1 over-expression was
recently reported [47]. Likewise, Myc represses p53-
induced apoptosis in leukemia cells and selectively pre-
vents p53 target gene transcriptional activation [48,49].
Differentially expressed Myc targets also included miR-
NAs. Thus, miR-29a and miR-181a are both confirmed
transcriptional targets of MYC  family members which
repress miR-29a [25] but induce miR-181a transcription
[26]. Interestingly, miR-181a and miR-221 were strongly
over-expressed in the cells of resistant patients (Fig. 5 C
and D), confirming a previous association of miR-181a
and miR-221 with poor prognosis [8] but contradicting
another report that low miR-181a expression levels are
associated with disease progression [9]. High levels of
miR-181a and miR-221 also point to cell cycle progres-
sion as both miRNAs repress CDKN1B (p27) expression
in hematologic diseases [23,50] and p27 was also found
down-regulated in resistant cells (Additional file 5). Nota-
bly, miR-181a also targets phosphatases that modulate
the activity of signaling kinases such as Zap-70 [51]; thus
reinforcing the interest for this miRNA in CLL research.
Table 3: Transcript levels of prognosis gene markers in B cells of CLL patients before treatment with fludarabine.
CLL-11 CLL-2 CLL-3R2 CLL-4 CLL-5 CLL-6R2
ATM 1.00 3 1.10 0.42 3 1.91 0.52 3 2.32
BLM 1.00 0.54 1.32 0.79 0.92 2.06
CDK2AP1 1.00 0.52 2.59 0.33 0.70 1.75
DCLRE1A 1.00 1.26 2.84 0.12 1.27 3.11
MYC 1.00 1.36 20.33 4 0.95 1.42 34.39 4
PCNA 1.00 0.43 2.85 0.59 0.61 1.49
SULF2 1.00 0.4 72.6 4.8 2.5 157.4
TP53 1.00 0.94 0.04 5 1.12 0.70 0.62 5
UMPS 1.00 0.73 1.33 0.71 0.73 1.53
XPC 1.00 0.98 0.23 1.43 1.56 0.43
1 Ct values from this patient were used for normalization to compare expression levels between patients with the ΔΔCt calculation method.
2 Patient number followed by "R" indicates the refractoriness character to fludarabine.
3 A mono-allelic deletion on 11q22 was observed.
4 A gain on 8q was observed.
5 A mono-allelic deletion on 17p13 was observed.Moussay et al. Molecular Cancer 2010, 9:115
http://www.molecular-cancer.com/content/9/1/115
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We also noticed that miR-29a was down-regulated in
cells of resistant patients. In CLL, miR-29a levels have
been reported to inversely correlate with TCL1 oncogene
expression [24]. Studies using other cellular models indi-
cate that miR-29a can activate p53 and induce apoptosis
in a p53-dependent manner [52]. Our observation that
the levels of miR-29a are lower in resistant patients is in
agreement with these previous findings and suggests the
Figure 5 Relationship between gene expression before treatment and sensitivity to fludarabine in CLL patients. Expression levels of the tar-
gets were investigated by RT-qPCR and normalized to both housekeeping genes. The average expression level in sensitive patients was used as cali-
brator. Expression levels presented as mean values ±SEM were investigated on two groups of CLL patients; eighteen patients in vivo (8S and 10R) and 
twenty-one patients in vitro (16S and 5R). Statistical analysis was performed by 2-sided t-test and levels were considered to be significantly different 
when p values were lower than 0.05. A and B. The expression of MYC and SULF2 was measured in CLL B cells of patients before their treatment with 
fludarabine in vivo (A) and in vitro (B). C and D. The expression of miR-29a, miR-181a, and miR-221 was investigated in CLL B cells of patients before 
their treatment with fludarabine in vivo (C) and in vitro (D).Moussay et al. Molecular Cancer 2010, 9:115
http://www.molecular-cancer.com/content/9/1/115
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importance of this regulation in aggressive CLL cases.
Taken together, our data therefore underline the crucial
and opposite role of the Myc and p53 gene regulatory
networks in determining the cell response to fludarabine
in CLL. Furthermore they underline the attraction of
using Myc inhibition as an approach for improving CLL
therapy. Amplification of Myc (i(8q)) in some CLL cases
[53] reinforces this notion [54].
Conclusions
Although a recent report reinforces the prominent role of
TP53 mutation as a prognosis tool for CLL [55], our work
lends supports to other studies which have challenged the
prognostic value of aberrations in master regulators such
as  ATM  and  TP53  [56,57]. Furthermore, our research
considerably extends previous studies by identifying the
oncogene  MYC  as over-expressed in B cells of CLL
patients resistant to fludarabine in vivo and in vitro, and
establishing the aberrant regulation of Myc-transcrip-
tional target genes and miRNAs in these patients. Our
data therefore support the importance of MYC in CLL
pathology and its association with poor prognosis, as sug-
gested by cytogenetic analyses [58]. They also underline
the importance of the tumor microenvironment in the
progression of CLL in vivo. Furthermore our work leads
us to propose that the expression levels of MYC, SULF2,
miR-29a, miR-181a and  miR-221a  measured in CLL
patients could be of interest during clinical trials and may
help to predict the chemo-refractory character of
patients. Finally, Myc inhibition may be of high value in
the treatment of poor prognosis CLL patients.
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